$GBLX
GB SCIENCES INC

2024 Q4 Form 10-Q Financial Statement

#000143774924036323 Filed on November 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$157.8K
YoY Change -71.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$32.74K
YoY Change -127.92%
Pretax Income -$190.5K
YoY Change -56.12%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$190.5K
YoY Change -56.12%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 407.1M 407.1M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.320K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $93.77K
YoY Change -59.96%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets $93.77K
Total Long-Term Assets
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $112.5K
YoY Change 48.75%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.441M
YoY Change 12.14%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.441M
Total Long-Term Liabilities
Total Liabilities $5.873M
YoY Change 19.2%
SHAREHOLDERS EQUITY
Retained Earnings -$110.5M
YoY Change 1.03%
Common Stock $40.82K
YoY Change 1.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.780M
YoY Change
Total Liabilities & Shareholders Equity $93.77K
YoY Change -59.96%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$190.5K
YoY Change -56.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
407071028
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
407071028
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
406071028
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
406071028
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55462
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3733133
dei Entity Address Address Line1
EntityAddressAddressLine1
9205 W. Russell Road, Suite 240
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89148
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
721-0297
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
407071028
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2320 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11991 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
91451 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
91451 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
93771 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
103442 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
520710 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
457093 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
112500 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 usd
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1437307 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1437307 usd
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1060825 usd
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1060825 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5441430 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5095557 usd
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
432000 usd
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
322000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5873430 usd
CY2024Q1 us-gaap Liabilities
Liabilities
5417557 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
40821 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
40721 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104722056 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104712156 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110542536 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110066992 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5779659 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5314115 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93771 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103442 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
157790 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
551491 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
411927 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
816614 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-157790 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-551491 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-411927 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-816614 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
32736 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
42742 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
63617 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
83546 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
160000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
235000 usd
CY2024Q3 gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
CY2023Q3 gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
-42194 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32736 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
117258 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63617 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109260 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-190526 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-434233 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-475544 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-707354 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-190526 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-434233 usd
us-gaap Net Income Loss
NetIncomeLoss
-475544 usd
us-gaap Net Income Loss
NetIncomeLoss
-707354 usd
CY2024Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-0 usd
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
269218 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3462 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
269218 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-190526 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-703451 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-479006 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-976572 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
407071028
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
395738723
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
406565533
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
388843528
us-gaap Profit Loss
ProfitLoss
-475544 usd
us-gaap Profit Loss
ProfitLoss
-707354 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
624 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
219168 usd
gblx Gain Loss On Collection Of Notes Receivable
GainLossOnCollectionOfNotesReceivable
-0 usd
gblx Gain Loss On Collection Of Notes Receivable
GainLossOnCollectionOfNotesReceivable
235000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30556 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
42194 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-69937 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
169756 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9060 usd
gblx Increase Decrease In Accrued Liabilities Excluding Interest Payable
IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable
112500 usd
gblx Increase Decrease In Accrued Liabilities Excluding Interest Payable
IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
63617 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
52990 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129671 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-517825 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
0 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
235000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
235000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
220196 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
110000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
75000 usd
gblx Payments For Brokerage Fees For Exercise Of Warrants
PaymentsForBrokerageFeesForExerciseOfWarrants
-0 usd
gblx Payments For Brokerage Fees For Exercise Of Warrants
PaymentsForBrokerageFeesForExerciseOfWarrants
17753 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
277443 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9672 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5382 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11991 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109912 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2320 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
104530 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
gblx Patent Filing And Drafting Costs Capitalized In Intangible Assets
PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets
0 usd
gblx Patent Filing And Drafting Costs Capitalized In Intangible Assets
PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets
7700 usd
CY2024Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
3462 usd
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
269218 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4680504 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
usd
CY2023Q3 gblx Exercise Of Warrants For Stock Value
ExerciseOfWarrantsForStockValue
220196 usd
CY2023Q3 gblx Adjustments To Additional Paid In Capital Brokerage Fees On Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalBrokerageFeesOnExerciseOfWarrants
-17753 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
219168 usd
CY2023Q3 gblx Adjustments To Additional Paid In Capital Warrant Reinstatement And Repricing
AdjustmentsToAdditionalPaidInCapitalWarrantReinstatementAndRepricing
269218 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
269218 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-434233 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4693126 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5589133 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-190526 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5779659 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4407383 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-0 usd
gblx Exercise Of Warrants For Stock Value
ExerciseOfWarrantsForStockValue
220196 usd
gblx Adjustments To Additional Paid In Capital Brokerage Fees On Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalBrokerageFeesOnExerciseOfWarrants
-17753 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
219168 usd
gblx Adjustments To Additional Paid In Capital Warrant Reinstatement And Repricing
AdjustmentsToAdditionalPaidInCapitalWarrantReinstatementAndRepricing
269218 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
269218 usd
us-gaap Net Income Loss
NetIncomeLoss
-707354 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4693126 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5314115 usd
gblx Exercise Of Warrants For Stock Value
ExerciseOfWarrantsForStockValue
10000 usd
gblx Adjustments To Additional Paid In Capital Warrant Reinstatement And Repricing
AdjustmentsToAdditionalPaidInCapitalWarrantReinstatementAndRepricing
-3462 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3462 usd
us-gaap Net Income Loss
NetIncomeLoss
-475544 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5779659 usd
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectability of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies.  These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. The actual results the Company experiences <em style="font: inherit;"> may </em>differ materially and adversely from these estimates.</p>
CY2024Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
42194 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
624 usd
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
177877867
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
183656554
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110542536 usd
CY2024Q3 gblx Working Capital Deficit
WorkingCapitalDeficit
-5347659 usd
CY2023Q3 gblx Working Capital Deficit
WorkingCapitalDeficit
-4992115 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129671 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-517825 usd
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1869307 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
-0 usd
CY2024Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
1869307 usd
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1759307 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
-0 usd
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
1759307 usd
CY2024 gblx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
23006492
CY2024 gblx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0.01
CY2024 gblx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
25348467
CY2024 gblx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.01
CY2024 gblx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
38337538
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
82079164
CY2024Q2 gblx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
CY2024Q2 gblx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0
CY2024Q2 gblx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1000000
CY2024Q2 gblx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.01
CY2024Q2 gblx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
6293335
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
74785829
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2700000
CY2024 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
28883334
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.06
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
28883334
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.06

Files In Submission

Name View Source Status
0001437749-24-036323-index-headers.html Edgar Link pending
0001437749-24-036323-index.html Edgar Link pending
0001437749-24-036323.txt Edgar Link pending
0001437749-24-036323-xbrl.zip Edgar Link pending
ex_750342.htm Edgar Link pending
ex_750343.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gblx-20240930.xsd Edgar Link pending
gblx20240930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gblx20240930_10q_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gblx-20240930_pre.xml Edgar Link unprocessable
gblx-20240930_def.xml Edgar Link unprocessable
gblx-20240930_cal.xml Edgar Link unprocessable
gblx-20240930_lab.xml Edgar Link unprocessable